Prospective, Open-label Trial to Evaluate Efficacy of 30-day Duration of Fidaxomicin in Patients With Recurrent C. Difficile Infection
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Fidaxomicin (Primary)
- Indications Clostridium-difficile-infections
- Focus Therapeutic Use
- 12 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Sep 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2018.
- 12 Sep 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2017.